Belzutifan (Welireg) Receives FDA Nod for Pheochromocytoma & Paraganglioma
FDA – U.S. Food and Drug Administration (FDA) approved Belzutifan (brand name Welireg, developed by Merck & Co.) for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL)